联系我们
联系人：陈先生
产品展示
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
点击次数：907
价格：￥电议
更新日期：2026/8/24 23:18:11
生 产 地：欧洲
产品型号：
商家名片
陈**
联系我时，请说明是阿仪网看到的，谢谢!
- 电话: 05*******891
- 手机: 18******628
- 微信:
- 交换名片后展示联系方式 → →
相关标签：FLT4,Fc,Human,重组人血管内皮生长因子受体3,Fc嵌合体
详细内容
慧嘉生物您实验身边的好伙伴
为客户提供“最高品质的产品”和“最优质的服务”
AssayBiotech CUSABIO Immunoway Santa Abcam Cst jackson Pierce Sigma Amresco Qiagen Cayman abnova millipore invitrogen merk ebioscience prospec lifespan BD
欢迎广大客户咨询，另有大量宣传海报和小礼品赠送。
网站：www..com
Q Q：
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
FLT4 Fc Human/重组人血管内皮生长因子受体3 Fc嵌合体
产品编号：PKA-245
产品规格：2μg/10μg/1mg
Synonyms Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. Introduction All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. Description Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. Solubility It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below
-18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 90.0% as determined by（a）Analysis by RP-HPLC.
（b）Analysis by SDS-PAGE. Biological Activity Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
产品规格：2μg/10μg/1mg
| Synonyms | Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-like TYROSINE KINASE 4, VEGFR-3. |
| Introduction | All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases （RTKs） characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular ａnd lymphatic endothelial cells ａnd to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis ａnd lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid （aa） residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain ａnd a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C ａnd VEGF-D have been shown to bind ａnd activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. |
| Description | Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids ａnd having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding. The FLT4 Fc Chimera is purified by proprietary chromatographic techniques. |
| Source | Insect Cells. |
| Physical Appearance | Sterile Filtered White lyophilized （freeze-dried） powder. |
| Formulation | FLT4 Fc Chimera was lyophilized from a concentrated （1 mg/ml） sterile solution containing no additives. |
| Solubility | It is recommended to reconstitute the lyophilized FLT4 Fc Chimera in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. |
| Stability | Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C. For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）. Please prevent freeze-thaw cycles. |
| Purity | Greater than 90.0% as determined by（a）Analysis by RP-HPLC. （b）Analysis by SDS-PAGE. |
| Biological Activity | Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 μg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml. |
| Usage | ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals. |
FLT4,Fc,Human,重组人血管内皮生长因子受体3,Fc嵌合体
